Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $154.3 million.

  • Intellia Therapeutics' Share-based Compensation fell 50.52% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year decrease of 31.13%. This contributed to the annual value of $154.3 million for FY2024, which is 15.09% up from last year.
  • Per Intellia Therapeutics' latest filing, its Share-based Compensation stood at $154.3 million for FY2024, which was up 15.09% from $134.1 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Share-based Compensation registered a high of $154.3 million during FY2024, and its lowest value of $19.9 million during FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Share-based Compensation value was $134.1 million (recorded in 2023), while the average stood at $126.6 million.
  • Data for Intellia Therapeutics' Share-based Compensation shows a peak YoY soared of 136.19% (in 2021) over the last 5 years.
  • Over the past 5 years, Intellia Therapeutics' Share-based Compensation (Yearly) stood at $19.9 million in 2020, then spiked by 136.19% to $47.0 million in 2021, then soared by 94.43% to $91.4 million in 2022, then skyrocketed by 46.66% to $134.1 million in 2023, then climbed by 15.09% to $154.3 million in 2024.